What is your preferred first line therapy for advanced NSCLC with an EGFR activating mutation?
Does the more recent NEJ026 trial describing benefit from Bevacizumab plus Erlotinib over Erlotinib alone in patients with EGFR driver mutations change current practice?
https://clinicaltrials.gov/ct2/show/NCT02633189
Community PollStarted
What is your preferred first line therapy for metastatic, EGFR+ NSCLC?
34 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Wexner Medical Center at The Ohio State University
Answered on
My current off-protocol approach is osimertinib as a single agent, though combining osimertinib with bevacizumab is being tested in an interesting clinical trial. The bev-erlo combination trials are very small with small hints of a survival benefit, but definitely improved progression-free survival....
Join for free or sign in to see the full answer